Analysts Expect OvaScience Inc. (OVAS) to Announce -$0.43 EPS
Wall Street analysts predict that OvaScience Inc. (NASDAQ:OVAS) will post earnings per share of ($0.43) for the current quarter, Zacks reports. Two analysts have made estimates for OvaScience’s earnings. The highest EPS estimate is ($0.39) and the lowest is ($0.46). OvaScience reported earnings per share of ($0.54) in the same quarter last year, which indicates a positive year-over-year growth rate of 20.4%. The company is expected to issue its next earnings report on Thursday, November 2nd.
According to Zacks, analysts expect that OvaScience will report full year earnings of ($1.96) per share for the current financial year, with EPS estimates ranging from ($2.36) to ($1.67). For the next financial year, analysts forecast that the firm will post earnings of ($1.49) per share, with EPS estimates ranging from ($1.78) to ($1.02). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for OvaScience.
OvaScience (NASDAQ:OVAS) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.45) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.02. The firm had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.09 million. OvaScience had a negative return on equity of 69.13% and a negative net margin of 16,132.47%. The business’s quarterly revenue was down 55.6% on a year-over-year basis. During the same quarter last year, the firm earned ($0.62) EPS.
Several brokerages have issued reports on OVAS. Zacks Investment Research raised OvaScience from a “sell” rating to a “hold” rating in a report on Wednesday. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of OvaScience in a research note on Thursday, August 3rd. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of OvaScience in a research note on Friday, May 12th. Finally, Credit Suisse Group reiterated an “underperform” rating and set a $1.00 target price on shares of OvaScience in a research note on Tuesday, April 18th.
Shares of OvaScience (NASDAQ OVAS) opened at 1.42 on Friday. The firm’s market cap is $50.67 million. The stock has a 50 day moving average price of $1.55 and a 200-day moving average price of $1.51. OvaScience has a 52-week low of $1.25 and a 52-week high of $8.98.
TRADEMARK VIOLATION WARNING: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.watchlistnews.com/analysts-expect-ovascience-inc-ovas-to-announce-0-43-eps/1476325.html.
Several large investors have recently made changes to their positions in the company. Jennison Associates LLC increased its stake in shares of OvaScience by 0.4% in the second quarter. Jennison Associates LLC now owns 2,191,258 shares of the biotechnology company’s stock valued at $3,418,000 after buying an additional 7,731 shares during the period. Wells Fargo & Company MN increased its stake in shares of OvaScience by 28.8% in the second quarter. Wells Fargo & Company MN now owns 164,283 shares of the biotechnology company’s stock valued at $256,000 after buying an additional 36,720 shares during the period. Northern Capital Management LLC increased its stake in shares of OvaScience by 92.6% in the first quarter. Northern Capital Management LLC now owns 91,865 shares of the biotechnology company’s stock valued at $172,000 after buying an additional 44,175 shares during the period. UBS Asset Management Americas Inc. acquired a new stake in shares of OvaScience during the first quarter valued at $107,000. Finally, LMR Partners LLP acquired a new stake in shares of OvaScience during the second quarter valued at $145,000. Institutional investors and hedge funds own 63.54% of the company’s stock.
OvaScience Company Profile
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.